Short-acting betaagonists and asthma

[摘要] Having initially worked in an era when we were told we were missing asthma (then the so-called cough-variant asthma), we move to a time of overdiagnosis and National Institute for Health and Care Excellence (NICE) guidelines to prove or disprove, such as unavailable FeNO concentrations, and risk of other labels such as silent reflux …There is no doubt that overuse of short-acting beta-agonists (SABAs)1 is dangerous, costly (especially if salbutamol is used or substituted by the pharmacy), and environmentally harmful, but what does the author suggest for a person who only wheezes on exposure to cats, such as when visiting a relative? A standby SABA or a long-acting muscarinic antagonist (LAMA)/inhaled corticosteroid (ICS), noting that they may not be used for months or years on end and then just once or twice?© British Journal of General Practice 2022REFERENCE 1.↵Ryan D (2022) Reducing short-acting beta-agonist overprescribing in asthma. [Editorial]. Br J Gen Pract, DOI: https://doi.org/10.3399/bjgp22X720485.

[学科分类] 卫生学